Emcutix Biopharmaceuticals Ltd in partnership with Canada-based Mantra Pharma Inc—both subsidiaries of Emcure Pharmaceuticals Ltd—has launched Ureaderm 10% and 20%, a new range of urea-based moisturizers designed to address severe dryness and skin conditions such as psoriasis and ichthyosis. This product is now available across India.
Ureaderm is formulated using Multilayer Fatty Acid Emulsion (MLFAE) technology, which enables a sustained release of urea to ensure deep and prolonged hydration for up to 72 hours. Supported by global research on the effectiveness of urea concentrations ranging from 5% to 40%, the Ureaderm range offers scientifically grounded solutions for skin hydration and restoration.
In addition to urea, the formulation includes key ingredients such as eicosapentaenoic acid (EPA), gamma-linolenic acid (GLA), and allantoin. These components work synergistically to strengthen the skin’s lipid barrier, minimize moisture loss, and improve skin texture and softness. The 10% formulation is intended for regular use in daily skincare routines, while the 20% version provides intensive moisturization for managing hyperkeratotic conditions requiring stronger keratolytic action.
Established in 2024, Emcutix Biopharmaceuticals Ltd focuses on dermatology and aesthetic medicine. Supported by Emcure Pharmaceuticals Ltd, the company is dedicated to delivering innovative, evidence-based treatments through strategic partnerships and a differentiated portfolio across therapeutic and aesthetic skincare.
Emcure Pharmaceuticals is a leading Indian pharmaceutical company headquartered in Pune, with a strong presence in over 70 countries, including key markets in Europe and Canada. Established in 1981, Emcure is ranked as the 12th largest pharmaceutical company in India by domestic sales as of MAT June 2024*. The company is driven by research and development, focusing on the creation and manufacture of differentiated, high-quality pharmaceutical products that address critical needs across multiple therapeutic areas. Renowned for its commitment to innovation, quality, and patient well-being, Emcure continues to play a vital role in advancing global healthcare.
